The Molecular Mechanisms and Therapeutic Strategies of EMT in Tumor Progression and Metastasis

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2022 Sep 8

PMID 36076302

Authors

Yuhe Huang

Weiqi Hong

Xiawei Wei

Affiliations

Soon will be listed here.

Abstract

Epithelial-mesenchymal transition (EMT) is an essential process in normal embryonic development and tissue regeneration. However, aberrant reactivation of EMT is associated with malignant properties of tumor cells during cancer progression and metastasis, including promoted migration and invasiveness, increased tumor stemness, and enhanced resistance to chemotherapy and immunotherapy. EMT is tightly regulated by a complex network which is orchestrated with several intrinsic and extrinsic factors, including multiple transcription factors, post-translational control, epigenetic modifications, and noncoding RNA-mediated regulation. In this review, we described the molecular mechanisms, signaling pathways, and the stages of tumorigenesis involved in the EMT process and discussed the dynamic non-binary process of EMT and its role in tumor metastasis. Finally, we summarized the challenges of chemotherapy and immunotherapy in EMT and proposed strategies for tumor therapy targeting EMT.

Citing Articles

Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research.

Bou Antoun N, Afshan Mahmood H, Walker A, Modjtahedi H, Grose R, Chioni A Int J Mol Sci. 2025; 26(5).

PMID: 40076427 PMC: 11898767. DOI: 10.3390/ijms26051799.

Radiogenomic Landscape of Metastatic Endocrine-Positive Breast Cancer Resistant to Aromatase Inhibitors.

Khanyile R, Chipiti T, Hull R, Dlamini Z Cancers (Basel). 2025; 17(5).

PMID: 40075655 PMC: 11899325. DOI: 10.3390/cancers17050808.

H2AJ Is a Direct Androgen Receptor Target Gene That Regulates Androgen-Induced Cellular Senescence and Inhibits Mesenchymal Markers in Prostate Cancer Cells.

Heidari Horestani M, Atri Roozbahani G, Baniahmad A Cancers (Basel). 2025; 17(5).

PMID: 40075640 PMC: 11898987. DOI: 10.3390/cancers17050791.

Advanced Therapeutic Approaches for Metastatic Ovarian Cancer.

Choe S, Jeon M, Yoon H Cancers (Basel). 2025; 17(5).

PMID: 40075635 PMC: 11898553. DOI: 10.3390/cancers17050788.

CYP2A6 suppresses hepatocellular carcinoma via inhibiting SRC/Wnt/β-Catenin pathway.

Liu Y, Feng L, Zhang W, Zhang X, Shao L, Zhao X Acta Pharmacol Sin. 2025; .

PMID: 40069491 DOI: 10.1038/s41401-025-01524-8.

References

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Dhar M, Lam J, Walser T, Dubinett S, Rettig M, Di Carlo D . Functional profiling of circulating tumor cells with an integrated vortex capture and single-cell protease activity assay. Proc Natl Acad Sci U S A. 2018; 115(40):9986-9991. PMC: 6176626. DOI: 10.1073/pnas.1803884115. View

Paoli P, Giannoni E, Chiarugi P . Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013; 1833(12):3481-3498. DOI: 10.1016/j.bbamcr.2013.06.026. View

Derynck R, Weinberg R . EMT and Cancer: More Than Meets the Eye. Dev Cell. 2019; 49(3):313-316. PMC: 7672963. DOI: 10.1016/j.devcel.2019.04.026. View

Strauss R, Li Z, Liu Y, Beyer I, Persson J, Sova P . Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One. 2011; 6(1):e16186. PMC: 3021543. DOI: 10.1371/journal.pone.0016186. View

Tong Z, Cai M, Wang X, Kong L, Mai S, Liu Y . EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 2011; 31(5):583-94. DOI: 10.1038/onc.2011.254. View

Battula V, Evans K, Hollier B, Shi Y, Marini F, Ayyanan A . Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells. 2010; 28(8):1435-45. PMC: 3523728. DOI: 10.1002/stem.467. View

Cao Z, Livas T, Kyprianou N . Anoikis and EMT: Lethal "Liaisons" during Cancer Progression. Crit Rev Oncog. 2016; 21(3-4):155-168. PMC: 5451151. DOI: 10.1615/CritRevOncog.2016016955. View

Lin Y, Wu Y, Li J, Dong C, Ye X, Chi Y . The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J. 2010; 29(11):1803-16. PMC: 2885925. DOI: 10.1038/emboj.2010.63. View

10.

Chockley P, Keshamouni V . Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression. J Immunol. 2016; 197(3):691-8. PMC: 4955875. DOI: 10.4049/jimmunol.1600458. View

11.

Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R . miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology. 2010; 52(6):2148-57. PMC: 3076553. DOI: 10.1002/hep.23915. View

12.

Valk-Lingbeek M, Bruggeman S, van Lohuizen M . Stem cells and cancer; the polycomb connection. Cell. 2004; 118(4):409-18. DOI: 10.1016/j.cell.2004.08.005. View

13.

Yilmaz M, Christofori G . EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28(1-2):15-33. DOI: 10.1007/s10555-008-9169-0. View

14.

Caramel J, Papadogeorgakis E, Hill L, Browne G, Richard G, Wierinckx A . A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013; 24(4):466-80. DOI: 10.1016/j.ccr.2013.08.018. View

15.

Goossens S, Vandamme N, Van Vlierberghe P, Berx G . EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. Biochim Biophys Acta Rev Cancer. 2017; 1868(2):584-591. DOI: 10.1016/j.bbcan.2017.06.006. View

16.

Ocana O, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S . Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell. 2012; 22(6):709-24. DOI: 10.1016/j.ccr.2012.10.012. View

17.

Xu Y, Lee D, Feng Z, Xu Y, Bu W, Li Y . Breast tumor cell-specific knockout of inhibits cancer cell plasticity, dissemination, and lung metastasis in mice. Proc Natl Acad Sci U S A. 2017; 114(43):11494-11499. PMC: 5664488. DOI: 10.1073/pnas.1618091114. View

18.

Manjunath Y, Upparahalli S, Avella D, Deroche C, Kimchi E, Staveley-OCarroll K . PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer. Cancers (Basel). 2019; 11(6). PMC: 6628040. DOI: 10.3390/cancers11060806. View

19.

Redfern A, Spalding L, Thompson E . The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome. Clin Exp Metastasis. 2018; 35(4):285-308. DOI: 10.1007/s10585-018-9906-x. View

20.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View